EU Recommends Revoking Approval for Vasculitis Drug Tavneos

An EU regulatory committee has recommended the revocation of marketing authorization for Tavneos, a drug for the rare disease vasculitis, following reports of patient deaths and concerns that its benefits do not outweigh the risks; a Japanese pharmaceutical company is discussing the situation with its government.